Table 2:
Summary of novel targets in RCC, with the corresponding drugs and selected clinical trials.
| Molecular Targets | Drugs (when applicable) |
State of Development | Selected Clinical Trials (when applicable) |
|---|---|---|---|
| HIF-2α | Belzutifan (MK-6482) | Clinical* |
NCT04195750 (Phase III) NCT04736706 (Phase III) NCT04586231 (Phase III) |
| MESH1 | - | Preclinical | - |
| SLC7A11 | - | Preclinical | - |
| Profilin 1 | - | Preclinical | - |
| TBK1 | - | Preclinical | - |
| IGF1R | Linsitinib | Preclinical | - |
| CDK4/6 | Palbociclib, Abemaciclib | Clinical | NCT03905889 (Phase Ib) |
| TIM-3 | Sabatolimab (MBG453) | Clinical | NCT02608268 (Phase I/II) |
| LAG-3 | Eftilagimod alpha (IMP321) | Clinical | NCT00351949 (Phase I) |
| XmAB22841 | Clinical | NCT03849469 (Phase I) | |
| TLRs | VTX-2337 (TLR8 agonist) NKTR-262 (TLR7/8 agonist) |
Clinical |
NCT02650635 (Phase Ib) NCT03435640 (Phase I/II) |
| STING pathway | - | Preclinical | - |
*:
Approved in patients with Von-Hippel Lindau (VHL)-associated ccRCC, in clinical development in patients with sporadic ccRCC